Array Biopharma clinical trials

Acquired by Pfizer, Jul 30, 2019 · source ↗

The registry lists 31 studies whose lead sponsor is Array Biopharma. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 5, 2022.

Studies

Recruiting first, then most recently updated. Showing 31 of 31. All Pfizer studies →

• A Safety Study of ARRY-371797 in Healthy SubjectsCompletedNCT00790049Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-438162 in Patients With Rheumatoid ArthritisCompletedNCT00650767Phase 2

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLCWithdrawnNCT02109653Phase 2

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-334543 in Patients With Advanced CancerCompletedNCT00278902Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-142886 in Patients With Advanced CancerCompletedNCT00085787Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-334543 in Patients With Advanced CancerCompletedNCT00637702Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Safety Study of ARRY-300 in Healthy SubjectsCompletedNCT00828165Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-334543 and Docetaxel in Patients With Advanced CancerCompletedNCT00833326Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic CardiomyopathyWithdrawnNCT01556568Phase 2

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-334543 and Capecitabine in Patients With Advanced CancerCompletedNCT00710736Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Safety Study of ARRY-403 in Patients With Type 2 DiabetesCompletedNCT00952198Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid TumorsCompletedNCT01469130Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Safety Study of ARRY-502 in Healthy SubjectsCompletedNCT01349725Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01363232Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E MutationsCompletedNCT01352273Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01248923Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-520 in Patients With Advanced CancerCompletedNCT00462358Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-382 in Patients With Selected Advanced or Metastatic CancersCompletedNCT01316822Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-371797 in Patients With Rheumatoid ArthritisCompletedNCT00729209Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic FunctionTerminatedNCT02050815Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-438162 (MEK162) in Patients With Advanced CancerCompletedNCT00959127Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal MelanomaTerminatedNCT01801358Phase 1/2

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT01649336Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromeCompletedNCT00916227Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromesCompletedNCT01496495Phase 1

  Sponsor listed in the registry: Array Biopharma, now a wholly owned subsidiary of Pfizer · First submitted before Array Biopharma became part of Pfizer

• Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway MutationsCompletedNCT02278133Phase 1/2

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer

• A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid TumorsCompletedNCT01449058Phase 1

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer

• LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer

• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedNCT01777776Phase 1/2

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer

• A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic CancerCompletedNCT00862524Phase 1/2

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer

• A Safety Study of ARRY-403 in Patients With Type 2 DiabetesCompletedNCT00859755Phase 1

  Sponsor listed in the registry: Array BioPharma · First submitted before Array BioPharma became part of Pfizer